OCGNOcugen, Inc.

Nasdaq ocugen.com


$ 1.26 $ 0.10 (8.47 %)    

Friday, 26-Apr-2024 16:59:04 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 1.28
$ 1.22
$ 0.00 x 0
$ 0.00 x 0
$ 1.20 - $ 1.30
$ 0.35 - $ 2.11
5,390,899
na
312.74M
$ 1.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-16-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-21-2023 06-30-2023 10-Q
4 05-05-2023 03-31-2023 10-Q
5 02-28-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-05-2022 06-30-2022 10-Q
8 05-06-2022 03-31-2022 10-Q
9 02-28-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-06-2021 06-30-2021 10-Q
12 05-07-2021 03-31-2021 10-Q
13 03-19-2021 12-31-2020 10-K
14 11-06-2020 09-30-2020 10-Q
15 08-14-2020 06-30-2020 10-Q
16 05-08-2020 03-31-2020 10-Q
17 03-27-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-09-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 03-22-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-15-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-10-2017 06-30-2017 10-Q
28 05-11-2017 03-31-2017 10-Q
29 03-16-2017 12-31-2016 10-K
30 11-10-2016 09-30-2016 10-Q
31 08-11-2016 06-30-2016 10-Q
32 05-12-2016 03-31-2016 10-Q
33 03-10-2016 12-31-2015 10-K
34 11-12-2015 09-30-2015 10-Q
35 08-12-2015 06-30-2015 10-Q
36 05-14-2015 03-31-2015 10-Q
37 03-27-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chardan-capital-maintains-buy-on-ocugen-raises-price-target-to-5

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and raises the price target from $4 to $5.

 ocugen-says-it-has-completed-dosing-of-subjects-with-geographic-atrophy-in-cohort-2-of-phase-12-armada-clinical-trial-of-ocu410a-modifier-gene-therapy

Company announced that dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a ...

 why-ocugen-shares-are-trading-higher

Ocugen shares are trading higher by 7.7% during Monday's session. The company announced U.S. FDA clearance of the IND amend...

 ocugen-reveals-us-fda-clearance-of-ind-amendment-to-begin-ocu400-phase-3-clinical-trial---first-gene-therapy-to-enter-phase-3-with-broad-retinitis-pigmentosa-indication

The Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the oth...

 why-ocugen-stock-is-climbing-today

Ocugen shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium ...

 ocugen-announces-positive-data-and-safety-monitoring-board-review-and-initiation-of-enrollment-in-medium-dose-for-ocu410-a-modifier-gene-therapy-in-phase-12-armada-study-for-geographic-atrophy

Three subjects with geographic atrophy (GA) were dosed in the Phase 1/2 clinical trial to date. An additional three subjects wi...

 why-ocugen-shares-are-popping-off
Why Ocugen Shares Are Popping Off
04/03/2024 15:44:44

Ocugen shares are trading higher by 14% during Wednesday's session. The company provided an update on its business activiti...

 signet-jewelers-dave--busters-entertainment-blue-owl-capital-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.

 hc-wainwright--co-reiterates-buy-on-ocugen-maintains-7-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price tar...

 earnings-scheduled-for-april-2-2024

Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter.

 reported-earlier-ocugen-ocu410st-advances-in-gardian-study-for-stargardt-disease-with-dsmb-approval-for-medium-dose-enrollment

Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial DSMB Determination to Proceed with Medium...

 oxford-industries-posts-weak-results-joins-applied-therapeutics-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

U.S. stock futures were higher this morning, with the Dow futures gaining by over 100 points on Monday.

 whats-going-on-with-ocugen-stock

Ocugen shares are trading lower by 6.3% during Tuesday's session. The stock is pulling back after hitting a new 52-week hig...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION